For nearly half a century, vitamin C's reputation in oncology has been shaped by one man's downfall. Linus Pauling, the Nobel Prize-winning chemist, spent his later career promoting the idea that very high doses of vitamin C could help treat cancer. When subsequent trials using vitamin C tablets found no benefit, the theory was widely dismissed as a scientific embarrassment.
New research suggests Pauling may not have been entirely wrong, according to a report published by The Conversation and syndicated by ScienceDaily. The catch, scientists now understand, is that the form of vitamin C matters enormously. A pill and an intravenous drip are, in this context, almost two different substances.
Why the delivery method changes everything
The human body tightly regulates how much vitamin C stays in the bloodstream after it is swallowed. The gut absorbs only a limited amount, and the kidneys quickly filter out any excess, meaning oral supplements cannot push blood concentrations very high no matter the dose.
Injecting vitamin C directly into a vein bypasses those controls entirely. Research summarised by the Frederick National Laboratory, part of the US National Cancer Institute, found that a phase 1 clinical study revealed that ascorbate concentrations could safely reach 25-30 mM with intravenous infusion of 100 g of vitamin C, levels roughly 100 to 500 times higher than oral supplementation can achieve. At those concentrations, sustained plasma levels around 10 mM for at least four hours were, based on preclinical studies, sufficient to kill cancer cells.
At such high concentrations, vitamin C stops behaving like a nutrient and starts acting more like a targeted drug. Inside tumour tissue, it appears to generate hydrogen peroxide, a reactive molecule that many cancer cells struggle to detoxify because they lack the enzyme levels healthy cells rely on to break it down. A review published by researchers at Amsterdam UMC's Cancer Center Amsterdam described high-dose intravenous vitamin C's role as a cancer-specific, pro-oxidative cytotoxic agent, anti-cancer epigenetic regulator and immune modulator, capable of reversing epithelial-to-mesenchymal transition and boosting immune response.
Encouraging but early clinical results
The strongest recent clinical signal comes from the University of Iowa. A randomised phase 2 trial testing high-dose intravenous vitamin C alongside chemotherapy in patients with stage 4 metastatic pancreatic cancer, one of the deadliest cancers with historically poor survival odds, produced results striking enough that researchers stopped the study early. The University of Iowa's Carver College of Medicine reported that results from the randomized, phase 2 clinical trial show that adding high-dose, intravenous vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer.
“"When you give very high doses, the vitamin C converts and makes hydrogen peroxide. And the hydrogen peroxide, the tumor cells can't handle," a member of the Iowa research team explained, describing the mechanism behind the effect, according to Iowa broadcaster KCRG.”
Beyond potentially slowing tumour growth, several early-phase trials cited by the Amsterdam UMC researchers suggest high-dose IV vitamin C may also ease some of the toxic side effects of chemotherapy, an appealing prospect for patients already coping with gruelling treatment schedules.
Why caution still applies
Medical charities and oncology bodies across Europe have long urged scepticism about vitamin C as a cancer therapy, and that caution has not disappeared. Cancer Research UK has repeatedly noted that despite encouraging laboratory results, there's certainly no evidence yet from any clinical trial that vitamin C improves cancer survival across the broader patient population, a position based on the absence of large, definitive trials rather than doubt about the underlying biology.
That gap between promising early data and proof at scale is precisely where the science currently sits. As the ScienceDaily-syndicated report put it, modern research has confirmed that intravenous vitamin C reaches much higher levels in the blood and has distinct biological effects, but what we do not yet have are large, definitive randomized trials showing that high-dose intravenous vitamin C clearly prolongs life for most cancer patients.
For European patients, the practical takeaway is straightforward. High-dose intravenous vitamin C is being studied at institutions including Weill Cornell Medicine in the United States and Sun Yat-sen University Cancer Center in China, but it remains an investigational add-on, not an approved alternative to chemotherapy, radiotherapy or surgery. Anyone considering it should discuss the option openly with their oncology team rather than seeking it from unregulated clinics, and should not delay or replace standard, evidence-based cancer care.
This article is free to read. It always will be — no paywall, no account, no tracking.
